OpenEvidence Acquires AI-Powered Amaro to Revolutionize Healthcare Advertising

In a major move, OpenEvidence has announced its acquisition of Amaro, an AI-native advertising startup backed by Google Ventures and Greycroft. Founded by brothers Kush Khosla and Sauren Khosla, Amaro specializes in using intelligent automation to analyze and optimize end-to-end advertising deployment for companies.

Sangeen Zeb, general partner at GV, expressed excitement, stating, "I've had the privilege of backing both OpenEvidence and Amaro, and it's thrilling to see them join forces. The Khosla brothers have built an exceptional team—combining resilience, vision, and technical excellence. This acquisition is a perfect fit, as Amaro's team and technology will help OpenEvidence accelerate its growth and expand access to trusted tools for clinicians."

This partnership enhances OpenEvidence's platform, scaling its capabilities for healthcare professionals by integrating Amaro's innovative advertising infrastructure. Zachary Ziegler, cofounder of OpenEvidence, highlighted the impact: "OpenEvidence powers over half a million clinical conversations daily for free to verified American clinicians. We believe every patient deserves care from physicians with access to the world's highest quality information. Our ad-supported model ensures that practices of all resource levels can leverage this technology. The Amaro team's speed, relentless shipping, and obsession with quality make this acquisition a natural fit that accelerates our vision."

The deal follows OpenEvidence's recent $210 million Series B financing, which valued the company at $3.5 billion. Currently, over 40% of physicians in the United States use OpenEvidence daily for high-stakes clinical decisions, with the platform adding 90,000 clinicians per month. This acquisition underscores OpenEvidence's momentum in building the nation's dominant medical search and AI platform for healthcare professionals.